DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock closed at 2.82 per share at the end of the most recent trading day (a 9.3% change compared to the prior day closing price) with a volume of 107.72K shares and market capitalization of 107.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. DiaMedica Therapeutics Inc. CEO is Rick Pauls.

The one-year performance of DiaMedica Therapeutics Inc. stock is 81.69%, while year-to-date (YTD) performance is 78.47%. DMAC stock has a five-year performance of -9.03%. Its 52-week range is between 1.27 and 4.75, which gives DMAC stock a 52-week price range ratio of 44.54%

DiaMedica Therapeutics Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 1.09, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -0.12, a ROA of -30.74%, a ROC of -31.87% and a ROE of -32.08%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from DiaMedica Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. DiaMedica Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for DiaMedica Therapeutics Inc. is Strong Buy (1), with a target price of $12, which is +325.53% compared to the current price. The earnings rating for DiaMedica Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DiaMedica Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DiaMedica Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.29, ATR14 : 0.22, CCI20 : 94.80, Chaikin Money Flow : -0.05, MACD : 0.06, Money Flow Index : 62.04, ROC : 8.40, RSI : 54.81, STOCH (14,3) : 49.47, STOCH RSI : 0.38, UO : 47.93, Williams %R : -50.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DiaMedica Therapeutics Inc. in the last 12-months were: David J. Wambeke (Buy at a value of $949 203), Dietrich John Pauls (Buy at a value of $49 997), Giuffre Randall Michael (Buy at a value of $254 150), Kellen Scott (Buy at a value of $39 100), Pauls Dietrich John (Buy at a value of $49 997), Pilnik Richard (Buy at a value of $149 999), Pilnik Richard D. (Buy at a value of $149 999), Randall Michael Giuffre (Buy at a value of $366 777), Semba Charles (Buy at a value of $49 997), Semba Charles Pauling (Buy at a value of $49 997), Von Koch Thomas (Buy at a value of $4 999 999), Wambeke David J. (Buy at a value of $150 003)